A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer
| Autor: | Jochen M. Schwenk, Rainer Heuchel, Johan Permert, Burcu Ayoglu, Sam Ghazi, Isabelle Magalhaes, Brigitta Omazic, Markus Maeurer, Jonas Mattsson, Zuzana Potácová, Ralf Segersvärd, Nils Albiin, Liu Zhenjiang, Thomas Poiret, Caroline S. Verbeke, Peter Nilsson, Matthias Löhr, Alexei Terman, Olle Ringdén, Nikolaos Kartalis |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Pathology medicine.medical_treatment Immunology Hematopoietic stem cell transplantation 03 medical and health sciences 0302 clinical medicine Immune system Internal medicine Pancreatic cancer Immunology and Allergy Medicine Radical surgery Survival rate Pharmacology business.industry medicine.disease Transplantation surgical procedures operative 030104 developmental biology 030220 oncology & carcinogenesis Adenocarcinoma business Progressive disease |
| Zdroj: | Journal of immunotherapy (Hagerstown, Md. : 1997). 40(4) |
| ISSN: | 1537-4513 |
| Popis: | We examined the immunologic effects of allogeneic hematopoietic stem cell transplantation (HSCT) in the treatment of pancreatic ductal adenocarcinoma, a deadly disease with a median survival of 24 months for resected tumors and a 5-year survival rate of 6%. After adjuvant chemotherapy, 2 patients with resected pancreatic ductal adenocarcinoma underwent HSCT with HLA-identical sibling donors. Comparable patients who underwent radical surgery, but did not have a donor, served as controls (n=6). Both patients developed humoral and cellular (ie, HLA-A*01:01-restricted) immune responses directed against 2 novel tumor-associated antigens (TAAs), INO80E and UCLH3 after HSCT. Both TAAs were highly expressed in the original tumor tissue suggesting that HSCT promoted a clinically relevant, long-lasting cellular immune response. In contrast to untreated controls, who succumbed to progressive disease, both patients are tumor-free 9 years after diagnosis. Radical surgery combined with HSCT may cure pancreatic adenocarcinoma and change the cellular immune repertoire capable of responding to clinically and biologically relevant TAAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|